News coverage about Insmed (NASDAQ:INSM) has trended positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a coverage optimism score of 0.29 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4322902536084 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of Insmed (NASDAQ:INSM) traded up $0.27 during trading hours on Thursday, hitting $26.52. The company had a trading volume of 45,563 shares, compared to its average volume of 951,329. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1,970.42, a P/E ratio of -8.48 and a beta of 1.09. Insmed has a 1 year low of $11.49 and a 1 year high of $33.94.

Several research analysts have recently commented on the company. Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Robert W. Baird reiterated a “positive” rating and set a $42.00 price target (up previously from $32.00) on shares of Insmed in a report on Thursday, January 4th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Insmed in a report on Thursday, January 4th. BidaskClub lowered Insmed from a “hold” rating to a “sell” rating in a report on Friday, January 26th. Finally, ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $36.67.

In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the sale, the director now directly owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.03% of the stock is currently owned by company insiders.

WARNING: “Insmed (INSM) Receiving Positive Media Coverage, Study Finds” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with's FREE daily email newsletter.